Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has announced the launch of its enhanced Medical Education Suite (MES), an AI-powered clinical skills training platform designed to improve the delivery and evaluation of Objective Structured Clinical Examinations (OSCEs) in medical education. The system was successfully deployed at the University of Minnesota Medical School with over 240 third-year students participating in a large-scale rollout that incorporated AI-simulated patients developed using the company's Global Library of Medicine (GLM).
The GLM is Treatment.com AI's proprietary medical knowledge engine, comprising over 10,000 expert medical reviews and structured to support diagnostic reasoning across more than 1,000 diseases and 15,000 symptoms. According to the company, MES integrates this AI engine to offer real-time scoring and objective evaluation, potentially saving as much as 40% in administrative costs, based on initial calculations from the University of Minnesota.
Dr. Kevin Peterson, Founder and Chief Medical Officer of Treatment.com AI, stated in the press release, "The Medical Education Suite reflects years of development in diagnostic reasoning and knowledge engineering. By introducing structured, AI-simulated patients alongside live simulated patients, and offering objective real-time scoring, we're helping students build stronger clinical skills in the classroom."
The University of Minnesota reported technical reliability during implementation, and faculty noted that the MES allowed delivery of a high-stakes OSCE at scale while ensuring consistent and objective evaluations. Professor Claudio Violato, Assistant Dean at the University of Minnesota Medical School, said, "Partnering with Treatment.com AI gave us the opportunity to explore how clinically governed AI can strengthen the way we assess and support student learning." He added that the MES represents a meaningful advancement in the evolution of medical education.
Preliminary findings from the deployment were shared at the 2025 annual Group on Information Resources (GIR) meeting of the Association of American Medical Colleges (AAMC) in Minneapolis. Further scientific publications detailing the results are currently in preparation by the university and company teams.
Treatment.com AI stated it is now engaging with additional institutions across North America, the UK, and other international OSCE markets to expand MES adoption.
AI Reshaping the Healthcare Landscape: Innovation, Integration, and Industry Adoption
Artificial intelligence continued to reshape healthcare in 2025, with several reports underscoring its transformative impact across diagnostics, education, administration, and innovation. According to the U.S. Chamber of Commerce, AI played a central role in solving some of the world's most urgent health challenges. In its June summary of global efforts, the Chamber noted that both public and private sector actors aimed to "significantly improve patient and public health outcomes worldwide" through responsible AI deployment.
The Chamber highlighted diagnostic advancements as a key area, referencing international research that demonstrated AI-powered tools could classify heart disease with 93% accuracy. It also pointed to the growing role of AI in personalizing treatment plans, predicting outcomes, and optimizing drug discovery. "AI used in diagnostics may have different risk profiles and regulatory needs compared to AI used in administrative processes within hospitals and healthcare systems," the report explained, advocating for tailored regulation in healthcare to maintain innovation without compromising patient safety.
Operational efficiency was another focus, particularly as global healthcare systems faced workforce shortages. The Chamber further reported that AI systems were streamlining administrative tasks such as scheduling and billing, allowing clinical professionals to prioritize patient care. Diana Pankevich, Global Innovation Policy Lead at Pfizer Inc., emphasized the need for regulation to evolve alongside the technology, stating, "As AI technology advances, the regulatory frameworks that govern its use must be equally dynamic and responsive."
Broader healthcare infrastructure trends also pointed to rapid technological integration. A report from Future Market Insights on June 12 projected that the wireless healthcare asset management market would rise from US$52.06 billion in 2025 to US$155.40 billion by 2035. This growth was attributed to the increasing adoption of AI, Internet of Things (IoT), and real-time tracking technologies by hospitals. The report explained that these tools were being used to monitor assets such as infusion pumps and surgical tools, optimize maintenance schedules, and improve patient safety through predictive analytics.
Alongside asset management, AI's use in clinical and operational settings was driven by increasing digitization. Cloud-based systems allowed real-time access to equipment data and enabled predictive maintenance and compliance tracking. The report noted a trend toward integrating AI-driven platforms with electronic health records (EHRs) and hospital information systems (HIS) to streamline resource allocation and enhance decision-making.
On June 12, Rustom Lawyer, writing for ET Insights, described generative AI (GenAI) as a catalyst for long-term healthcare innovation. He reported that the GenAI healthcare market was expected to grow from US$1.96 billion in 2024 to US$39.68 billion by 2034, driven by applications in drug discovery, clinical documentation, and workflow automation. According to the article, over 75% of major healthcare organizations had already begun scaling GenAI initiatives. Gartner projections cited in the piece stated that 30% of new drugs would be discovered using GenAI by 2025.
Funding patterns also reflected confidence in the sector. Global venture capital investments in GenAI reached US$45 billion in 2024, with healthcare firms capturing a significant share. According to the Deloitte Health Care Generative AI Outlook Survey, 90% of healthcare executives reported returns on AI investments. The article described how high-performing healthcare firms averaged US$6.4 million in annual AI spending to improve efficiency and outcomes.
Lawyer cautioned, however, that integration and regulation remained crucial. He emphasized that success would depend on AI's compatibility with legacy systems and the development of transparent, privacy-compliant solutions. As he noted, "The most effective applications will be those that prioritize usability and align with real-world healthcare needs."
What's Next for Treatment.com AI
Treatment.com AI's ongoing development of the MES platform is part of a broader strategy to position itself as a key technology provider within the evolving medical education landscape. According to the company's investor presentation, Treatment.com AI has a wide range of active partnerships with institutions such as the University of Minnesota and University of Edinburgh. It is also in discussions with a further 30 medical schools.
It is also in discussions with a further 30 medical schools.
The MES platform itself is supported by Treatment's Global Library of Medicine, a clinician-curated and AI-powered knowledge base that underpins diagnostic tools across the company's product line. The platform has been shown to reach a 92% diagnostic accuracy rate in past OSCE simulations, even when operated by non-medical undergraduates, demonstrating its potential effectiveness in both educational and clinical support environments.
Looking ahead, the company is looking to integrate its AI technologies into a range of services, including pharmacy support tools and mental health solutions. The recent acquisitions of Rocket Doctor has added over 500,000 patients and expanded the company's capabilities in telehealth and voice-based AI applications, as two examples. With growing healthcare AI market projections and increasing demand for scalable education tools, the MES initiative aligns with Treatment.com AI's broader push to enhance clinical outcomes and reduce systemic inefficiencies in healthcare delivery.
Analyst Highlights Growth Setup for AI Healthtech Firm
*On May 21, Technical Analyst Clive Maund released a positive assessment of Treatment.com AI Inc., suggesting the company was "positioning to be a major play in the AI transformation of healthcare."
Maund explained that Treatment.com AI had developed a physician-built platform aimed at resolving persistent inefficiencies in the healthcare system. The system integrated clinical intelligence, virtual care, and advanced voice assistant technology into a single ecosystem. He noted that its diagnostic tools, powered by the proprietary Global Library of Medicine (GLM), have the ability to offer consistent 24/7 availability and emotional responsiveness through voice AI capabilities.
He also highlighted the company's Rocket Doctor subsidiary, describing it as "a Shopify for physicians" and identifying it as a scalable model for remote care delivery.
From a technical perspective, Maund noted that the company's stock had completed a 3-wave A-B-C correction and was beginning to rise from key support levels. He described the move as emerging from a long-term base that had developed over the past 30 months.
Streetwise Ownership Overview*
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS;939:FRA)
"With the price just starting to advance off important support . . . the time is believed to be at hand for the stock to advance to break out above the key resistance," Maund wrote. He identified CA$1.08 to CA$1.12 as an initial target range, followed by a second target of CA$4.00, with further upside potential beyond those levels.
He also emphasized the significance of the volume pattern, stating that the strong buildup since early 2024 "supports a significant new uptrend developing from here." Maund concluded that the company's combination of sector positioning and chart signals made it "an excellent time to buy or add to positions in Treatment AI.com."
Ownership and Share Structure
According to Refinitiv, insiders own approximately 5.1% of Treatment.com AI. Institutions hold .81%. Retail investors own the remaining 94.1%.
The company has 75,502,398 million outstanding common shares. The market cap is approximately CA$35,486,127.06.
Over the past 52 weeks, the company traded between CA$0.0471 and CA$0.9116 per share.
| Want to be the first to know about interesting Healthcare Services and Life Sciences Tools & Diagnostics investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI Inc.
- James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
* Disclosure for the quote from the Clive Maund article published on May 21, 2025
- For the quoted article (published on May 21, 2025), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$1,500.
- Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing the article quoted. Maund received his UK Technical Analysts’ Diploma in 1989. The recommendations and opinions expressed in the article accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed
Clivemaund.com Disclosures
The quoted article represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be only be construed as a recommendation or solicitation to buy and sell securities.
